Injective's Price Hurdle: Can It Clear $5 and Keep Rising?

Injective's price has reached a critical level of $5 as it tests its recovery. This breakout from a descending triangle has pushed INJ directly into the 200-day EMA, and it must clear this hurdle to continue its upward momentum. According to Injective, the expansion of its tokenization infrastructure is a major factor in this growth. Recently, POSCO International and LG CNS launched a pilot using live trade data and real commercial receivables on Injective.AI agents reviewed Letters of Credit and supporting documents.

The network has already tokenized institutional funds, public equities, trade receivables, and pre-IPO shares involving companies like SpaceX and OpenAI. Moreover, Injective is now an SEC-registered transfer agent, making it the first layer 1 blockchain to combine native RWA infrastructure with regulated recordkeeping capabilities for American capital markets.

This development positions Injective as infrastructure for compliant capital markets that can serve institutions as well as everyday users. However, the market has yet to reward this ambition, and the Injective price must prove itself on the chart. A clean breakout above $5 could open the path towards $5.50 and then $6, but rejection would send INJ back towards $4 or lower.